Gene therapy is still experimental, and there are probably things we're going to learn.
When two participants in a sickle cell gene therapy trial developed blood cancers in 2021, medicine was reminded that even the most hopeful cures carry shadows that demand reckoning. Researchers at Dana-Farber and Boston Children's Hospital investigated whether clonal hematopoiesis — a condition where mutating blood stem cells multiply into distinct, potentially dangerous populations — might explain the elevated malignancy risk, only to find that sickle cell patients carry this condition at rates no different from the general population. The answer, it turns out, was not found, only narrowed: the mystery deepens even as the trials resume, and the broader truth emerges that sickle cell disease itself carries a cancer risk five to ten times higher than normal, independent of any therapy. Science here is not triumphant but honest — still searching, still obligated to its patients.
- Two participants in a bluebird bio gene therapy trial developed blood malignancies in 2021, forcing an abrupt halt to trials that had represented genuine hope of a cure for sickle cell disease.
- The leading hypothesis — that sickle cell patients carry elevated rates of clonal hematopoiesis, a condition that can multiply cancer risk tenfold — was tested against genomic data from over 3,000 sickle cell patients and more than 71,000 controls.
- The hypothesis failed: clonal hematopoiesis rates in sickle cell patients matched the general population, eliminating one explanation while leaving the cancer mechanism frustratingly unresolved.
- Researchers are now probing whether rare, hard-to-detect mutations or the physical processing of cells during gene therapy preparation may be seeding the risk — a finer and more technically demanding investigation.
- Trials have resumed, but the conversation with patients must now carry a harder truth: sickle cell disease itself confers a myeloid cancer risk rivaling recognized leukemia predisposition syndromes, a reality that demands transparency and long-term vigilance.
In early 2021, gene therapy trials for sickle cell disease — among the most promising paths toward an actual cure — were halted after two participants developed blood malignancies. The trials have since resumed at centers including Dana-Farber/Boston Children's, but the central question remains open: why did cancer appear, and what does it mean for patients weighing this treatment?
One hypothesis drew early attention. Sickle cell patients are already known to face elevated blood cancer risk as they age, and researchers wondered whether clonal hematopoiesis — a condition in which mutating blood stem cells form fast-multiplying populations that can raise cancer risk tenfold — might be more prevalent in this population, making them especially vulnerable when gene therapy intervened. Physician-researcher Vijay Sankaran and postdoctoral fellow Alex Liggett set out to test this by analyzing whole-genome sequencing data from more than 3,000 sickle cell patients alongside data from over 71,000 people without the disease.
The result was unexpected: clonal hematopoiesis rates in sickle cell patients were no higher than in the general population. Published in the Journal of Clinical Investigation in February 2022, the finding rules out one explanation — but deepens the mystery rather than resolving it. Sankaran notes that whole-genome sequencing cannot detect very small or rare clonal populations, and researchers are now investigating whether such rare mutations might arise from how cells are handled during gene therapy processing, or from the conditioning regimens administered beforehand.
The broader picture is sobering. Independent of gene therapy entirely, people with sickle cell disease face a myeloid cancer risk five to ten times higher than the general population — a largely understudied reality that rivals recognized leukemia predisposition syndromes. As sickle cell patients live longer, this background risk becomes impossible to set aside. Coauthor David A. Williams frames the ongoing research as foundational: understanding leukemia risk in this population is not academic, but essential to making gene therapy safer and to counseling patients with genuine honesty about what they face.
In early 2021, a promising path toward curing sickle cell disease came to an abrupt halt. Two people enrolled in a gene therapy trial sponsored by bluebird bio had developed blood malignancies—a complication serious enough to pause the work entirely. The trials have since resumed, including at Dana-Farber/Boston Children's Cancer and Blood Disorders Center, but the fundamental question lingers unanswered: Why did cancer emerge in these patients, and should people with sickle cell disease fear gene therapy as a result?
The stakes are high. Gene therapy has offered something sickle cell patients have rarely had: genuine hope of a cure, not merely management of a lifelong disease. Yet for patients weighing that possibility, the specter of cancer risk is real and personal. Vijay Sankaran, an attending physician at Dana-Farber/Boston Children's, captures the tension plainly: he is excited by what gene therapy might accomplish, but he knows his patients worry about malignancy.
One early hypothesis seemed plausible. People with sickle cell disease are known to face elevated risk of blood cancers as they age—a background risk that exceeds the general population. Researchers wondered whether a condition called clonal hematopoiesis might explain the trial cases. In this condition, blood stem cells acquire mutations that cause some populations to multiply faster than others, forming distinct clones. The condition can increase cancer risk tenfold. The theory was worth testing: perhaps sickle cell patients carried clonal hematopoiesis at higher rates than the general population, making them vulnerable when gene therapy intervened.
Sankaran's lab, led by postdoctoral fellow Alex Liggett, set out to investigate. They analyzed whole-genome sequencing data from more than 3,000 people with sickle cell disease and compared it to data from more than 71,000 people without the disease, searching for somatic mutations and clonal blood cell populations. The result was surprising: the rate of clonal hematopoiesis in sickle cell patients was no higher than in the general population. The hypothesis, at least at the level of detection available through whole-genome sequencing, did not hold.
This finding, published in the Journal of Clinical Investigation in February 2022, eliminates one explanation but deepens the mystery. Sankaran acknowledges that the study could not detect small clonal populations involving rare mutations—a gap that now becomes the focus of investigation. Researchers are exploring whether rare clones might arise from how cells are handled during gene therapy processing, or whether the conditioning regimens used before gene therapy might select for rare clones. The work continues through the National Heart, Lung, and Blood Institute's Cure Sickle Cell initiative, with collaborators in the United Kingdom now studying how cell processing itself might contribute to mutation development.
David A. Williams, chief of Hematology/Oncology at Boston Children's and a coauthor on the study, frames the work as essential groundwork. Understanding leukemia risk in sickle cell disease is not merely academic—it is foundational to making gene therapy safer. Yet the broader picture is sobering. Independent of gene therapy, people with sickle cell disease face a myeloid cancer risk five to tenfold higher than the general population, a risk that has not been well studied but rivals that of patients with recognized leukemia predisposition syndromes. As sickle cell patients live longer, this long-term cancer risk becomes impossible to ignore.
The field is learning to ask harder questions. Gene therapy remains experimental, and researchers acknowledge there is much still to discover. Patients may eventually be counseled through programs like Dana-Farber/Boston Children's Pediatric Cancer Genetic Risk Program, armed with better understanding of their individual risk. For now, the trials have resumed, but the conversation with patients must be more complete: gene therapy may offer cure, but it exists within a landscape of cancer risk that demands ongoing attention and transparency.
Citações Notáveis
For patients, cancer risk is a worry, even as gene therapy offers curative prospects— Vijay Sankaran, MD, PhD, Dana-Farber/Boston Children's
It is critical that the field understands this risk more completely so we can improve the safety of our gene therapy approaches— David A. Williams, MD, Boston Children's
A Conversa do Hearth Outra perspectiva sobre a história
Why did the trials stop if the gene therapy vectors themselves weren't causing the cancer?
Two people developed blood malignancies. That's enough to pause and investigate, even if the vectors weren't the culprit. The field needed to understand what was happening before moving forward.
So the study ruled out clonal hematopoiesis as the explanation. What does that actually mean for patients?
It means one theory about why these cancers occurred didn't pan out. But it also means we still don't know the real reason. That's both honest and unsettling.
Is sickle cell disease itself a cancer risk, separate from gene therapy?
Yes. People with sickle cell disease already face five to tenfold higher risk of certain blood cancers as they age. Gene therapy doesn't create that risk—it exists whether patients get treated or not.
Then why does gene therapy matter to this conversation?
Because gene therapy involves processing cells and using conditioning regimens that might select for rare mutations we can't yet detect. We need to know if the treatment itself is adding to an already elevated baseline risk.
What happens next?
Researchers are looking for rare clones and studying how cell processing affects mutation development. It's collaborative work, international. They're trying to make the therapy safer before more people enter trials.
Should someone with sickle cell disease avoid gene therapy because of cancer risk?
That's not a simple yes or no. They need full information: their baseline cancer risk, what we know and don't know about gene therapy's role, and what monitoring might look like. Then they decide.